- Research article
- Open Access
Mesenchymally-derived Insulin-like growth factor 1 provides a paracrine stimulus for trophoblast migration
© Lacey et al; licensee BioMed Central Ltd. 2002
- Received: 29 November 2001
- Accepted: 24 April 2002
- Published: 24 April 2002
Trophoblast migration into maternal decidua is essential for normal pregnancy. It occurs in a defined time window, is spatially highly restricted, and is aberrant in some pathological pregnancies, but the control mechanisms are as yet ill-defined. At the periphery of the placenta, chorionic villi make contact with decidua to form specialised anchoring sites that feed interstitially migrating cytotrophoblast into the placental bed.
Explants of first trimester mesenchymal villi on collagen type I developed cytotrophoblast outgrowths from the villous tips. However, in medium changed daily, cells did not progress to a migratory phenotype, remaining instead as a contiguous multi-layered sheet. This suggested the need for another migration stimulus. To test the possibility that this might arise from mesenchymal cells, serum-free conditioned medium from first trimester placental fibroblasts was added to explant cultures. Cytotrophoblasts were stimulated to migrate in streams across the gel. Affinity depletion of Insulin-like growth factor from fibroblast medium reduced streaming activity, while the addition of exogenous IGF-I (10 ng/ml) to serum-free medium produced a streaming phenotype. IGF receptor type 1 (IGFR1) was present on cells in the columns, and streaming could be inhibited by antibody to this receptor. IGF-II and activin, known stimulators of cytotrophoblast migration, were also active in this model.
These data suggest a paracrine interaction between villous mesenchyme and the cytotrophoblast in anchoring sites that stimulates trophoblast infiltration of decidua. Such a signal would be self-limiting since it diminishes with distance from the placenta. This is a novel mechanism in placental development.
- Fibroblast Conditioned Medium
- Villous Cytotrophoblast
- Extravillous Cytotrophoblast
- Trophoblast Migration
The placenta is the first organ to develop, vascularised chorionic villi being already evident during the third week of gestation. Indeed, rapid early development is a prerequisite for normal progression of the embryo. From these early stages, spatial segregation gives rise to two populations of placental villi, one that floats freely in the intervillous space, and a second population (anchoring villi) that acts to stabilise the mechanical integrity of the placental-maternal interface [1–4]. The surface of both types of structure is covered by trophoblast. The floating villi exhibit a bilayered epithelium consisting of cytotrophoblast with overlying syncytium, while the anchoring sites lack a continuous syncytium, featuring instead villous tips with multilayered columns of largely mononuclear cytotrophoblast [1, 5]. Villous cytotrophoblasts act as stem cells for both pathways. The syncytium functions as a transporting epithelium, while extravillous cytotrophoblasts in the distal columns provide physical anchorage of the villous tree, failure of which is likely to lead to miscarriage. The distal columns also act as feeder sites for a large population of migratory cytotrophoblasts that infiltrate the decidua and inner myometrium, where they colonise and transform the spiral arteries to allow increased blood flow to the intervillous space . Impaired transformation of the myometrial arterial segments is associated with pregnancy pathologies including pre-eclampsia [7, 8]. Such considerations underline the importance of understanding the mechanisms that control trophoblast differentiation and entry to the migratory or syncytial pathways.
Investigations of events that occur during formation of anchoring sites and the signals that lead to extravillous trophoblast differentiation require experimental systems that replicate as faithfully as possible placental development in vivo. We have used an explant model [5, 9–11] in which stem villous cytotrophoblast at the tips of mesenchymal villi is stimulated by attachment to an extracellular matrix (ECM) to undergo a proliferative burst. This is followed by cell reorganisation into a radial outgrowth that resembles the cytotrophoblast columns and shell seen in vivo, both in terms of morphology and the progressive expression of molecular markers of the extravillous pathway [9, 10]. The process depends on interaction between fibronectin deposited by the cytotrophoblasts and its receptor, integrin α5β1, at the cell surface . However, cell detachment from the distal column, migration and infiltration of the surrounding ECM as seen in vivo are not observed in vitro.
These findings suggest that whilst contact with a permissive ECM triggers the development of cytotrophoblast columns that function effectively in tissue anchorage, it is insufficient to stimulate the acquisition of a migratory phenotype. Thus, cell migration apparently requires a further stimulus. Using a placenta-decidua coculture system we have tested the possibility that this might arise from maternal decidual cells, but the results were remarkably similar to those seen in explants on cell-free ECM, suggesting that decidua may not be the source of a paracrine stimulus to trophoblast migration [9, 12]. In the light of these findings we have now investigated another potential source of paracrine effectors, namely the mesenchymal cell population that lies beneath the villous cytotrophoblast. At the base of cytotrophoblast columns, mesenchymal cells extend processes that approach and even make direct contact with the trophoblast basement membrane . In the current investigation we show that first trimester fibroblasts produce signals that activate cytotrophoblasts to migrate from the periphery of nascent columns, and that one component of the paracrine repertoire is insulin-like growth factor (IGF).
Trophoblast migration in explant culture is modulated by growth factors
Trophoblast cell lines, primary cell isolates and cells from placental explants have been previously observed to exhibit altered migratory activity in the presence of growth factors under various assay conditions. Activin  and IGF-II [14, 15] have both been reported to stimulate migration, while TGF-β1 has inhibitory effects mediated by alteration of the integrin repertoire expressed by these cells [14, 16].
Placental fibroblasts secrete factors that stimulate trophoblast migration
Placental mesenchymal cells produce IGF in vivo
IGF-I stimulates streaming-type migration of cytotrophoblasts
Depletion of IGF from fibroblast medium diminishes the migratory stimulus
Fibroblast conditioned medium was assayed for the presence of IGF-I using RIA. Levels of IGF-I in explant conditioned medium ranged from 2.8–7.2 ng/ml. In order to test the possibility that IGF-I action might stimulate trophoblast migration, the fibroblast conditioned medium was depleted of IGF-I using an affinity column, and screened post-depletion for migration-promoting activity in the explant model. The result was a remarkable reduction in cytotrophoblast streaming behaviour (Fig. 5c, Fig. 6). Cells lost their characteristic bipolar morphology and appeared mostly rounded.
The effect of IGF-I is mediated by the type 1 IGF receptor
The presence of IGFs at the maternal-fetal interface has been documented both in humans and a variety of animal species [18–20]. The importance of the IGF system to pregnancy outcome has been clearly demonstrated by the severe fetal growth restriction that occurs in mice lacking either IGF-I or IGF-II . There is evidence that fetal growth is dependent on IGF in humans . We have now identified IGF-I as an important component in placental mesenchymal-epithelial signalling. A role for the IGF system in promoting cytotrophoblast migration was suggested by the discovery that the extravillous cytotrophoblast of first trimester express mRNA encoding IGF-II [20, 21], together with the demonstration that IGF-II stimulates trans-filter migration in cultured cytotrophoblast [14, 15]. From these findings arose the idea of an autocrine loop in which trophoblast might enhance its own migration.
We have used an explant model in which de novo development of columns occurs specifically at the distal tips of first trimester mesenchymal villi [10, 11]. Columns retain normal polarity, with a stromal compartment beneath the villous basement membrane. In this model IGF-II and activin AA  stimulate cytotrophoblast migration, providing further evidence in favour of autocrine effects. Addition of IGF-1 however produces a striking streaming pattern of cytotrophoblast migration. The production of IGF-I in vitro by fibroblasts is consistent with low but significant levels of IGF-I mRNA in this location in vivo  as well as immunoreactivity indicating that the factor is present. IGF-I appears not to be produced by trophoblasts. However cytotrophoblast in columns expresses the receptors IGFR1 and IR as well as their intracellular target IRS-1. A fraction of placental IGFR1 heterodimerises with IR . IGFs can act through the insulin receptor .
We therefore postulate the existence of a paracrine mechanism that stimulates trophoblast migration (Fig. 8). Further work will be required to investigate the part played by the IGF/insulin receptor family in trophoblast migration, including other intracellular targets and the phenotypic alterations that confer increased motility. There are suggestions that other receptor species including the IGFR2/M6P receptor may be capable of signal transduction and effects on trophoblast motility [15, 24].
In this model, as trophoblast migrates more deeply into the decidua and myometrium, it progresses farther away from the villous mesenchyme where IGF-I originates, so the magnitude of the signal must clearly diminish. This suggests the possibility of a self-limiting mechanism for migration, in which local inhibitory stimuli eventually outweigh the stimulatory signal. The reason for the presence of both autocrine (IGF-II) and paracrine (IGF-I) stimuli is as yet unclear, though IGF-I produces a more notable streaming phenotype. An alternative interpretation is that the paracrine trigger might act simply as a switch to a migratory pattern of behaviour. The two IGFs differ in their effects on proliferation and differentiation of rat trophoblast . The role of IGF binding proteins and in particular IGFBP-1, which is a major secretory product of decidual cells [18, 20], in regulation of the IGF system at the maternofetal interface remains to be resolved [14, 18, 26].
Extravillous cytotrophoblast differentiation requires at least two distinct steps (Fig. 8). In the first step, a column forms as a result of attachment to ECM. In the second step, IGF-I from placental mesenchymal cells stimulates progression to a fully migratory phenotype. This leads to a model in which, as the trophoblast migrates further away form its site of origin at the anchoring villus, through the decidua and into the myometrium, the migratory stimulus becomes diluted. Thus a mechanism is suggested whereby trophoblast migration might cease in the inner myometrium. Escape from paracrine regulation is likely to be a feature of trophoblastic tumours. Whether the IGF system also plays a role in the normal colonisation and transformation of maternal spiral arteries, and whether it may be affected in the major pregnancy pathologies of pre-eclampsia, IUGR and spontaneous abortion, remains to be investigated.
Collagen type I (rat tail tendon) was obtained from Beckton Dickenson (Oxford, UK) and Matrigel from Stratech Scientific (Luton, UK). Dulbecco's Eagle's Medium (DMEM), Ham's F-12 and fetal calf serum (FCS) were from Gibco (Life Technologies, Paisley, UK). Human Activin AA was a kind gift from the National Hormone and Pituitary Program, NIDDK (Dr Parlow). Rabbit anti-mouse streptavidin-FITC and biotinylated rabbit anti-mouse-Ig were from Dako (High Wycombe, UK). Human recombinant IGF-I was obtained from Genentech (San Francisco, USA), recombinant human TGFβ1 from R&D Systems (Abingdon, UK). Monoclonal anti-cytokeratin 7 was from Dako (Ely, UK). Monoclonal antibody αIR3 to IGFR1 was from Calbiochem (Nottingham, UK). Monoclonal Ab-1 to IGFR1 was a kind gift from Prof K Siddall, University of Cambridge, UK. Monoclonal antibody 15C9 to IGF-I was as described previously .
Normal first trimester (8–12 week) placenta was obtained by elective surgical or medical termination of pregnancy. Tissue was collected in PBS supplemented with antibiotic and antimycotic solution (AAM; Sigma, Poole, UK) prior to dissection. The results obtained using the explant system were independent of collection method.
The explant culture method was as described in Aplin et al. Dissected mesenchymal villous tissue was arranged radially on 80 μl drops of collagen type I gel, covered with 20 μl of serum-free medium (SFM; an equal mixture of DMEM and Ham's F12 (Gibco, Paisley, UK), supplemented with 1% AAM) and incubated overnight at 37°C, 5% CO2 to allow attachment. Wells were then carefully flooded with 1 ml SFM and incubated at 37°C, 5% CO2.
After an initial period of 24 h during which cytotrophoblast proliferation occurs at the villous tips to produce anchoring cell columns , growth factors or fibroblast conditioned SFM were added to the culture medium. IGF-I (10 ng/ml), TGF-β1 (4 ng/ml), activin AA (10 ng/ml) or IGF-II (10 ng/ml) were added daily to the culture medium and subsequent growth characteristics monitored by light microscopy. In addition, explants were cultured with monoclonal antibody Ab-1 (1 μg/ml) to human IGF receptor 1 (IGFR1) added daily (with or without 10 μg/ml IGF-I), or in the presence of fibroblast conditioned SFM depleted of IGF-I using immunoaffinity chromatography (see below). Cultures were continued up to 7 days.
This assay has the significant advantage of allowing migratory behaviour to be observed in living trophoblast, because migration occurs largely across the surface of the gel. Thus whole mount examination can be undertaken without the need to produce thin sections. Outgrowths were examined qualitatively taking into account size, distance, the morphology of the constituent cells and their inter-relationships including cell-cell adhesion and sheet integrity. Semi-quantitative evaluation of cytotrophoblast outgrowths from explants was carried out by analysing individual sites at villous tips. Images of live cultures were captured using a an imaging system (KS400, Kontron Elektronik GmbH, Eching, Germany) coupled to a Leitz Diavert microscope. Outgrowth distance was evaluated on a scale of 0 (no outgrowth) to 3 (outgrowth > 1 mm from tissue edge). Cell morphology was described on a scale of 0 (tightly packed cells throughout the outgrowth) to 3 (majority elongated and radially-oriented cells). Note that the number of cells present is not evaluated, as this varies widely between sites and is critically dependent on the size of the area of contact between tissue and gel at the start of the explant, a parameter that varies with the shape of the villus. The two estimates were added together to produce a value in the range 1–6 for each site. At least 3 experimental series with replicates from different placentas were used for each treatment.
Fibroblasts were isolated and characterised from first trimester tissue as described previously  and routinely passaged in monolayer. In order to produce conditioned medium, cells just below confluence were incubated in serum-free medium for 3 days. IGF levels in this medium were measured using our previously reported RIA . Serum-free fibroblast conditioned medium was depleted of IGF-I by affinity chromatography. 1 ml of anti-IGF-I antibody 15C9 (1 mg/ml ) was coupled to activated Sephacryl, then the solid phase incubated with conditioned SFM for 16 h at 4°C. IGF-depleted medium was harvested by centrifugation at 2800 rpm,10 min, and the supernatant was filter-sterilised, aliquotted and stored at -20°C. RIA was used to confirm removal of IGF.
Fresh placental tissue and 4–7 day old explant cultures were snap frozen in OCT (Tissue-Tek, Cambridge, UK) and stored at -80°C. 6 μm cryosections were cut and mounted on poly-L-lysine-coated slides for immunocytochemical analysis. Cryosections were stained essentially as described previously . IGFR1 was localised with antibody αIR-3 (5 μg/ml). Antibody to cytokeratin 7 was used as a positive control marker to verify the identity of trophoblast .
IGF-I was measured by a previously reported modification of the functional separation method  in which excess IGF-II blocks the interference from IGFBPs . Briefly, samples were diluted 1:100 in acidic sample buffer and then incubated with 100 μg/l IGF-II, 125I-IGF-I (20 000 cpm) and anti-IGF-I antibody (1:4000 dilution of clone BPL-M23) at 4C, pH 7.8 for 16 h. Separation of bound and free radioligand was performed with anti-mouse IgG linked to cellulose (Sac-Cel; IDS, Tyne & Wear, UK) for 1 h at 37C, followed by centrifugation at 1000 g for 10 minutes at 4C. The detection limit, defined as 10% displacement of the binding at zero dose of IGF-I was 0.08 ng/tube and the inter- and intra-assay coefficients of variation were 5.2–7.4% and 4.0–5.7% respectively. Cross reactivity with IGF-II and insulin was <2% for both peptides.
We thank WellBeing for funding this work and Anne White for support and stimulating discussions. M Westwood is a Dorothy Hodgkin Research Fellow of the Royal Society.
- Enders AC: Fine structure of anchoring villi of the human placenta. Am. J. Anat. 1968, 122: 419-452.View ArticlePubMedGoogle Scholar
- Boyd JD, Hamilton WJ: The Human Placenta. The Macmillan Press, London. 1970Google Scholar
- Aplin JD, CJP Jones, Haigh T, Vicovac Lj, Church HJ: Anchorage in the developing placenta: an overlooked determinant of pregnancy outcome?. Human Fertility. 1998, 1: 75-79.View ArticlePubMedGoogle Scholar
- Aplin JD, Haigh T, Lacey H, Chen C-P, Jones CJP: Tissue interactions in the control of trophoblast invasion. J. Reprod. Fertil suppl. 2000, 1: 57-64.Google Scholar
- Vicovac Lj, Aplin JD: Epithelial-mesenchymal transition during trophoblast differentiation. Acta Anat. 1996, 156: 202-216.View ArticlePubMedGoogle Scholar
- Pijnenborg R, Dixon G, Robertson WB, Brosens I: Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta. 1980, 1: 3-19.View ArticlePubMedGoogle Scholar
- Robertson WB, Brosens I, Landells WN: Abnormal placentation. In: Obstetrics and Gynecology Annual. Edited by: RM Wynn. 1985, Appleton-Century Crofts, Norwalk, Connecticut, 14: 411-426.Google Scholar
- Pijnenborg R: Trophoblast invasion. Reprod. Med. Rev. 1994, 3: 53-73.View ArticleGoogle Scholar
- Vicovac Lj, Jones CJP, Aplin JD: Trophoblast differentiation during anchoring villus formation in a coculture model of the human implantation site in vitro. Placenta. 1995, 16: 41-56.View ArticlePubMedGoogle Scholar
- Aplin JD, Haigh T, Jones CJP, Church HJ, Vicovac Lj: Development of cytotrophoblast columns from explanted first trimester placental villi: role of fibronectin and integrin α5β1. Biol. Reprod. 1999, 60: 828-838.View ArticlePubMedGoogle Scholar
- Aplin JD, Lacey H, Haigh T, Jones CJP, Chen C-P, Westwood M: Growth factor-extracellular matrix synergy in the control of trophoblast invasion. Biochem. Soc. Transac. 1999, 28: 199-202.View ArticleGoogle Scholar
- Vicovac Lj, Papic N, Aplin JD: Tissue interactions in first trimester trophoblast-decidua cocultures. Trophoblast Res. 1993, 7: 223-236.Google Scholar
- Caniggia I, Lye SJ, Cross J: Activin is a local regulator of human cytotrophoblast cell differentiation. Endocrinology. 1997, 138: 3976-3986.PubMedGoogle Scholar
- Irving JA, Lala PK: Functional role of cell surface integrins on human trophoblast cell migration: regulation by TGF, IGF-II and IGFBP-1. Exp. Cell Res. 1995, 217: 419-427. 10.1006/excr.1995.1105.View ArticlePubMedGoogle Scholar
- Hamilton GS, Lysiak JJ, Han VK, Lala PK: Autocrine-paracrine regulation of human trophoblast invasiveness by insulin-like growth factor (IGF)-II and IGF-binding protein (IGFBP)-1. Exp. Cell Res. 1998, 244: 147-156. 10.1006/excr.1998.4195.View ArticlePubMedGoogle Scholar
- Caniggia I, Taylor CV, Knox Ritchie JW, Lye SJ, Letarte M: Endoglin regulates trophoblast differentiation along the invasive pathway in human placental villous explants. Endocrinology. 1997, 138: 4977-4988.PubMedGoogle Scholar
- Anson-Cartwright L, Dawson K, Holmyard D, Fisher SJ, Lazzarini RA, Cross JC: The glial cells missing-1 protein is essential for branching morphogenesis in the chorioallantoic placenta. Nat. Genet. 2000, 25: 311-314. 10.1038/77076.View ArticlePubMedGoogle Scholar
- Westwood M: Role of insulin-like growth factor binding protein 1 in human pregnancy. Rev. Reprod. 1999, 4: 160-167.View ArticlePubMedGoogle Scholar
- Baker J, Liu JP, Robertson EJ, Efstratiadis A: Role of insulin-like growth factors in embryonic and postnatal growth. Cell. 1993, 75: 73-82.View ArticlePubMedGoogle Scholar
- Han VKM, Carter AM: Spatial and temporal expression of mRNAs for IGFs and their binding proteins in the placenta of man and laboratory animals. Placenta. 2000, 21: 289-305. 10.1053/plac.1999.0498.View ArticlePubMedGoogle Scholar
- Ohlsson R, Holmgren L, Glaser A, Szpecht A, Pfeifer-Ohlsson S: Insulin-like growth factor 2 and short-range stimulatory loops in control of human placental growth. EMBO J. 1989, 8: 1993-1999.PubMed CentralPubMedGoogle Scholar
- Bailyes EM, Nave BT, Soos MA, Orr SR, Hayward AC, Siddle K: Insulin receptor/ IGF-I receptor hybrids are widely distributed in mammalian tissues: quantification of individual receptor species by selective immunoprecipitation and immunoblotting. Biochem J. 1997, 327: 209-215.PubMed CentralView ArticlePubMedGoogle Scholar
- Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A: Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene. 1999, 18: 2471-2479. 10.1038/sj/onc/1202600.View ArticlePubMedGoogle Scholar
- McKinnon T, Chakraborty C, Gleeson LM, Chidiac P, Lala PK: Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J. Clin. Endocrinol. Metab. 2001, 86: 3665-3674.View ArticlePubMedGoogle Scholar
- Kanai-Azuma M, Kanai Y, Kurohmaru M, Sakai S, Hayashi Y: Insulin-like growth factor (IGF)-I stimulates proliferation and migration of mouse ectoplacental cone cells, while IGF-II transforms them into trophoblastic giant cells in vitro. Biol. Reprod. 1993, 48: 252-261.View ArticlePubMedGoogle Scholar
- Irwin JC, Suen LF, Martina NA, Mark SP, Giudice LC: Role of the IGF system in trophoblast invasion and pre-eclampsia. Hum. Reprod. 1999, 14 (Suppl 2): 90-96.View ArticlePubMedGoogle Scholar
- Crosby SR, Tsigos C, Anderton CD, Gordon C, Young RJ, White A: Elevated plasma insulin-like growth factor binding protein-1 levels in type 1 (insulin-dependent) diabetic patients with peripheral neuropathy. Diabetologia. 1992, 35: 868-872.View ArticlePubMedGoogle Scholar
- Haigh T, Chen C-P, CJP Jones, Aplin JD: Studies of mesenchymal cells from 1st trimester human placenta: expression of cytokeratin outside the trophoblast lineage. Placenta. 1999, 20: 615-626. 10.1053/plac.1999.0441.View ArticlePubMedGoogle Scholar
- Gill MS, Whatmore AJ, Tillmann V, White A, Addison GM, Price DA, Clayton PE: Urinary IGF-I and IGF binding protein-3 in children with disordered growth. Clin. Endocrinol. Oxf. 1997, 46: 483-492. 10.1046/j.1365-2265.1997.1670981.x.View ArticlePubMedGoogle Scholar
- Blum WF, Breier BH: Radioimmunoassys for IGFs and IGFBPs. Growth Regul. 1994, 4: 11-19.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.